 SYDNEY, AUSTRALIA, April 16, 2021 GLOBE NEWSWIRE -- Immutep Limited ASX: IMM; NASDAQ: IMMP Immutep or the Company, is pleased to announce that it has received a A1,155,055 cash rebate from the Australian Federal Governments RD tax incentive program. The cash rebate provided in respect of expenditure incurred on eligible RD activities conducted in the 2020 fiscal year, mainly related to the Companys TACTI-mel and TACTI-002 clinical study using its lead compound eftilagimod alpha efti or IMP321, conducted in Australia. 